Harrow announced the launch of atropine.com, an ordering and marketing portal designed specifically for prescribers interested in compounded atropine formulations. All atropine.com prescriptions will be provided by ImprimisRx, a fully-owned subsidiary of Harrow.
“For many years, customers have consistently told us of their growing need for a trusted and reliable source of compounded atropine. A recent article highlighted that the quality of available compounded atropine formulations varies greatly, causing inconsistency in stability, potency, storage requirements, and product shelf life. We saw an opportunity to resolve these issues, create a family of compounded formulations of atropine, and support patients and eyecare professionals with unsurpassed customer service," Mark L. Baum, Harrow’s Chairman and Chief Executive Officer, said in a company news release.
"Our compounded atropine formulations undergo a strict series of validated analytical tests to ensure consistency, potency, and stability; they are stable at a biologically comfortable pH and are now available in three concentrations (0.01%, 0.025%, and 0.05%) for as low as $39 per bottle,” Mr. Baum added.
“While our current suite of compounded atropine formulations is available for individual patients through the ImprimisRx 503A national mail-order pharmacy, we intend to make a patent‑pending suite of compounded atropine formulations that does not contain either preservatives or boric acid. This suite of products will be available soon to healthcare facilities through our 503B outsourcing facility—with or without a patient-specific prescription," Mr. Baum said.